Circulation times of hepatocellular carcinoma cells by in vivo flow cytometry

2010 ◽  
Vol 8 (10) ◽  
pp. 953-956 ◽  
Author(s):  
李延 Yan Li ◽  
樊志超 Zhichao Fan ◽  
郭进 Jin Guo ◽  
刘光大 Guangda Liu ◽  
谭晓英 Xiaoying Tan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Flow Cytometry ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
In Vivo Flow Cytometry

Circulation times of prostate cancer and hepatocellular carcinoma cells by in vivo flow cytometry

2011 ◽  
Vol 79A (10) ◽  
pp. 848-854 ◽  
Author(s):  
Yan Li ◽  
Jin Guo ◽  
Chaofeng Wang ◽  
Zhichao Fan ◽  
Guangda Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hepatocellular Carcinoma ◽  
Flow Cytometry ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
In Vivo Flow Cytometry

scholarly journals CRISPR/Cas9-mediated genome engineering of CXCR4 decreases the malignancy of hepatocellular carcinoma cells in vitro and in vivo

2017 ◽  
Vol 37 (6) ◽  
pp. 3565-3571 ◽  
Author(s):  
Xiaoli Wang ◽  
Wenmei Zhang ◽  
Yan Ding ◽  
Xingrong Guo ◽  
Yahong Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Genome Engineering ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells

scholarly journals Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Wei Jiang ◽  
Tao Li ◽  
Jiaojiao Guo ◽  
Jingjing Wang ◽  
Lizhou Jia ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Carcinoma Cells ◽  
Therapeutic Effects ◽  
Single Chain ◽  
Antitumor Activities ◽  
Hepatocellular Carcinoma Cells ◽  
Car T Cells ◽  
Car T

T cells expressing chimeric antigen receptors, especially CD19 CAR-T cells have exhibited effective antitumor activities in B cell malignancies, but due to several factors such as antigen escape effects and tumor microenvironment, their curative potential in hepatocellular carcinoma has not been encouraging. To reduce the antigen escape risk of hepatocellular carcinoma, this study was to design and construct a bispecific CAR targeting c-Met and PD-L1. c-Met/PD-L1 CAR-T cells were obtained by lentiviral transfection, and the transfection efficiency was monitored by flow cytometry analysis. LDH release assays were used to elucidate the efficacy of c-Met/PD-L1 CAR-T cells on hepatocellular carcinoma cells. In addition, xenograft models bearing human hepatocellular carcinoma were constructed to detect the antitumor effect of c-Met/PD-L1 CAR-T cells in vivo. The results shown that this bispecific CAR was manufactured successfully, T cells modified with this bispecific CAR demonstrated improved antitumor activities against c-Met and PD-L1 positive hepatocellular carcinoma cells when compared with those of monovalent c-Met CAR-T cells or PD-L1 CAR-T cells but shown no distinct cytotoxicity on hepatocytes in vitro. In vivo experiments shown that c-Met/PD-L1 CAR-T cells significantly inhibited tumor growth and improve survival persistence compared with other groups. These results suggested that the design of single-chain, bi-specific c-Met/PD-L1 CAR-T is more effective than that of monovalent c-Met CAR-T for the treatment of hepatocellular carcinoma., and this bi-specific c-Met/PD-L1 CAR is rational and implementable with current T-cell engineering technology.

scholarly journals Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Xingxing He ◽  
Fang Liu ◽  
Jingjun Yan ◽  
Yunan Zhang ◽  
Junwei Yan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Carcinoma Cells ◽  
Mutant P53 ◽  
Hepatocellular Carcinoma Cells ◽  
Trans Splicing
Sign in / Sign up

Export Citation Format

Share Document